{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:43:37Z","timestamp":1779252217202,"version":"3.51.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T00:00:00Z","timestamp":1538611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Microbicide Trials Network"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI068633"],"award-info":[{"award-number":["UM1AI068633"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI068615"],"award-info":[{"award-number":["UM1AI068615"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI106707"],"award-info":[{"award-number":["UM1AI106707"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,19]]},"DOI":"10.1093\/cid\/ciy652","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T07:59:38Z","timestamp":1535615978000},"page":"1129-1135","source":"Crossref","is-referenced-by-count":17,"title":["Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048"],"prefix":"10.1093","volume":"68","author":[{"given":"Albert Y","family":"Liu","sequence":"first","affiliation":[{"name":"Bridge HIV, San Francisco Department of Public Health, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Statistical Center for HIV\/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter L","family":"Anderson","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Wagner","sequence":"additional","affiliation":[{"name":"Bridge HIV, San Francisco Department of Public Health, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Pan","sequence":"additional","affiliation":[{"name":"Statistical Center for HIV\/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Peda","sequence":"additional","affiliation":[{"name":"Statistical Center for HIV\/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailazarid","family":"Gomez","sequence":"additional","affiliation":[{"name":"FHI 360, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Beamer","sequence":"additional","affiliation":[{"name":"Magee-Womens Research Institute, Pittsburgh, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Magee-Womens Research Institute, Pittsburgh, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Strizki","sequence":"additional","affiliation":[{"name":"Merck & Co, Kenilworth, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlene S","family":"Dezzutti","sequence":"additional","affiliation":[{"name":"Magee-Womens Research Institute, Pittsburgh, Pennsylvania"},{"name":"School of Medicine, University of Pittsburgh, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanna M","family":"Piper","sequence":"additional","affiliation":[{"name":"National Institutes of Health, Division of AIDS, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"MTN-028 Protocol Team for the Microbicide Trials Network","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,10,4]]},"reference":[{"key":"key\n\t\t\t\t2019031909413452600_CIT0001","first-page":"83","article-title":"Antiretroviral preexposure prophylaxis for HIV prevention","volume":"368","author":"Baeten","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0002","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0003","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0004","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"Choopanya","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0006","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"Molina","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0007","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0008","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0009","unstructured":"Rees\n              H\n            , Delany-MorelweS, LombardC, et al\n          FACTS 001 phase III trial of pericoital tenofovir 1% gel for HIV prevention in women. Presented at: Conference on Retroviruses and Opportunistic Infections; February 23\u201326, 2015; Seattle, WA."},{"key":"key\n\t\t\t\t2019031909413452600_CIT0010","first-page":"995","article-title":"Dapivirine vaginal ring for HIV-1 prevention","volume":"376","author":"Baeten","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0011","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","article-title":"Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women","volume":"375","author":"Nel","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0012","unstructured":"Brown\n              E\n            , Palanee-PhilipsT, MarzinkeM, et al\n          Residual dapivirine ring levels indicate higher adherence to vaginal ring is associated with HIV-1 protection. Presented at: AIDS 2016; July 18\u201322, 2016; Durban, South Africa."},{"key":"key\n\t\t\t\t2019031909413452600_CIT0013","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1128\/AAC.49.12.4911-4919.2005","article-title":"Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1","volume":"49","author":"Strizki","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0014","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1086\/518797","article-title":"Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211","volume":"196","author":"Gulick","year":"2007","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0015","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1086\/650342","article-title":"Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial","volume":"201","author":"Suleiman","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0016","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/QAI.0b013e3181e2cba0","article-title":"Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients","volume":"54","author":"Wilkin","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0017","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jcv.2012.06.021","article-title":"Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc","volume":"55","author":"McNicholas","year":"2012","journal-title":"J Clin Virol"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0018","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.antiviral.2011.08.008","article-title":"Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes","volume":"92","author":"Scopelliti","year":"2011","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0019","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/AAC.01733-09","article-title":"Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates","volume":"55","author":"Van Wesenbeeck","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0020","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/cid\/ciy653","article-title":"Phase 1 safety and pharmacokinetics study of MK-2048\/vicriviroc (MK-4176)\/MK-2048A intravaginal rings","volume":"68","author":"Hoesley","year":"2019","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0021"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0022"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0023","author":"World Health Organization\/CONRAD"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0024","volume-title":"Investigator\u2019s brochure: MK-2048","author":"Merck & Co","year":"2005"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0025","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/jcph.248","article-title":"Expression of six drug transporters in vaginal, cervical, and colorectal tissues: implications for drug disposition in HIV prevention","volume":"54","author":"Nicol","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0026","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1021\/mp5005004","article-title":"Vaginal expression of efflux transporters and the potential impact on the disposition of microbicides in vitro and in rabbits","volume":"11","author":"Grammen","year":"2014","journal-title":"Mol Pharm"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0027","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.AOG.0000298338.58511.d1","article-title":"Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial","volume":"111","author":"Creinin","year":"2008","journal-title":"Obstet Gynecol"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0028","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1600-0897.2010.00932.x","article-title":"Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections","volume":"65","author":"Herold","year":"2011","journal-title":"Am J Reprod Immunol"},{"key":"key\n\t\t\t\t2019031909413452600_CIT0029","unstructured":"Keller\n              M\n            , LRayL, AtrioJ, et al\n          Early termination of a phase 1 trial of tenofovir disoproxil fumarate vaginal ring. Presented at: Conference on Retroviruses and Opportunistic Infections; 4\u20137 March 2018;Boston, MA. Abstract 1059 LB."}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/68\/7\/1129\/28114806\/ciy652.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T23:27:01Z","timestamp":1553038021000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/68\/7\/1129\/5115666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,4]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,10,4]]},"published-print":{"date-parts":[[2019,3,19]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy652","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4,1]]},"published":{"date-parts":[[2018,10,4]]}}}